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use averaged 21 hours for BIROAD and 19.2 hours for WEARIT. 
Conclusion: WD is a safe (<2.3% false shocks per patient-month) and effective (>25% 
effective resuscitation) alternative to EMS for outpatient populations with a temporary risk 
of SCA. 
2:1 5 p.m. 
826-2 Hospital Readmission After Cardloverter Def ibr i l la tor  
Implantation: Single Chamber Versus Dual Chamber 
Devices 
Ahmad AbouI-Karim. Hassir F. Marrouche, Soufian Almahameed, David O. Martin, 
Niranjan Seshedri, Robert A. Schweikert, Walid SeUba, Bruce wilkoff, Patdck Tchou, 
Andrea Natale, The Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: Dual chamber cardioverter defibrillators (ICD) have the capability to dis- 
criminate supraventricular from ventdcular arrhythmia and to maintain AV synchrony, 
which may be important for patients with a poor left ventricular function. The purpose of 
this study was to evaluate whether dual chamber ICDs have any advantage over single 
chamber ICDs in reducing number of cardiac re-hospitalization due to either inappropri- 
ate treatment or congestive heart failure. Methods end results: We report outcomes on 
a total of 461 patients (80% men: mean age 61+ 12 years) routinely followed at our insti- 
tution for at least 2 years. The median follw-up in this population was 36 months. Three 
hundred and ninety patients (85%) had single chamber and 71 patients (15%) had dual 
chamber ICD. Logistic regression was used to assess the relation between type of ICD 
end risk of hospitalization. The risk of being hopitalized at least once by admission indi- 
cation is given in the table. In unadjusted analyses as well as analyses that adjusted for 
age, sex, and ejection fraction, there were no statistically significant relationships 
between hospitalization and ICD type (P • 0.20). Conclusion: Cardiac related re-hospi- 
talization is common in patients with ICDs. The implantation of dual chamber ICD did not 
appear to reduce re-hospitalization for inappropriate shocks, device malfunction or heart 
failure. 
Indication for Admission Single Chamber (N=390) DualChamber(N=71) P-value 
Inappropriate Therapy 28 (7%) 7 (10%) 0.4 
Device Malfunction 40 (10%) 6 (8%) 0,67 
Heart Failure 86 (22%) 20 (28%) 0.23 
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826-3 Implantab le  Card iac  Def ibr i l la tor  Use in Patients With 
Arrhythmogenlc Right Ventricular Dysplaaia 
Allison M. Pdtchett, Paul A. Friedman, Win-Kuang Shen, Mayo Clinic Foundation, 
Rochester, Minnesota. 
Background: We sought to define the characteristics and outcomes of patients with 
arrhythmogenic right ventdcular dysplasia (ARVD) who underwent implentable cardiac 
defibrillator (iCD) placement. 
Methods: Ten patients were identified who had an ICD placed for a diagnosis of ARVD. 
A retrospective chart review was performed to characterize the population, outcomes of 
diagnostic testing, and previous therapies. In addition, patients were contacted by phone 
or survey to identify ICD utilization and adjunctive therapies 
Results: Of the 10 patients, ages ranged from 24-64 (ave 44.4 +14.0) years and 70% 
were women. The diagnostic evaluation included RV biopsy in 50% of patients, cine CT 
50%, and MR170%. EP testing results were available for 9 patients showing inducible VT 
in 77.8% (average 2.00 morphologies, all LBBB pattern). Prior to implantation, 4 of 10 
had taken antiarrhythmics. ICD implantation was undertaken for secondary prevention in 
80% (8/10), 40% out-of-hospital cardiac arrest and 40% sustained VT. The other 20% 
had nonsustained VT. At implantation the average DFT was 11.56 J, range 5-24J. The 
average R wave was 7.84 mV, range 3.5-17.1 inV. 50% required lead repositioning dur- 
ing or lead revision shortly after implantation due to inadequate pace/sense thresholds. 
During a mean follow-up of 41.0 months (range 9-90 months), 8 of 10 patients had 
received therapies from the ICD. The initial therapy occurred between 4 days to 51 
months after implantation. Atrial arrhythmias caused inappropriate treatment in only one 
patient. Additional antiarrhythmio therapy was required in 80% of patients. There were no 
deaths, clinical CHF, or transplantation. 
Conclusions: 1) Despite RV abnormalities, this cohort of symptomatic ARVD patients 
underwent successful transvenous Ice placement. 2) Careful follow-up of pace/sense 
parameters is required. 3) There was a high incidence of appropriate device discharges, 
with 80% requiring adjunctive antiarrhythmic therapy. 4) Given the absence of CHF and 
mortality in this cohort, arrhythmia management and sudden death prevention may 
enhance long-term survival. ICD use appears to play an important role in ARVD therapy. 
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826-4 Performance of the Electrogram Vector Timing and 
Correlation Algorithm for Discrimination of Ventrlcular 
Tachycardia From Supraventrlcular Tachycardla in 
Patients With Wide Sinus Rhythm QRS 
Joseph M. Smith. The Contak CD Investigators, Julie A. Thompson, Eric G. Lovett, Mark 
Schwartz, Joseph Bocek, Jaeho Kim, The Cardiovascular Group, Arlington, Virginia, 
Guidant Corporation, SL Paul, Minnesota. 
Background: Morphology based algodthms have been introduced in implantable cardio- 
verter defibrillators (ICDs) to discriminate ventricular tachycardia (V'F) from supraventric- 
ular tachycardia (SVT), however some of these algorithms have difficulty discriminating 
JACC March  6,  2002 
VT from SVT in patients who have wide QRS during sinus rhythm. Vector Timing and 
Correlation (V'i'C) is a novel algorithm designed to exploit not only the change in shock 
electrogram associated with V'I', but also the change in relative timing of the rate-sensing 
electrogram with respect to overall ventdcular activation. The goal of this study was to 
assess the performance of V'I'C in discriminating SVI" from V'I" in a subset of patients 
likely to pose the greatest difficulty for rhythm discrimination algorithms, ie, those with 
wide sinus QRS complexes in whom the rate sensing electrogram is derived from a 
broad bipole (left and right ventricle), typical of patients receiving resychronizafion ther- 
apy. 
Methods: Spontaneous tachycardia episodes were retrieved from VENTAK CONTAK 
CD ICD patient disks from 33 patients with wide baseline QRS (>120ms) as measured 
on a surface ECG. A segment of normal sinus rhythm from the shock channel electro- 
gram was used to generate a ventricular conduction reference for each patient. Shock 
channel arrhythmia complexes were aligned with the sinus reference by rate channel tim- 
ing and compared using correlation analysis to classify each complex as V'I" or SVI". 
Contextual classification of complexes was used to diagnose the arrhythmia. 
Results: Thirty-nine sustained spontaneous tachycardia episodes (29 VT, 10 SVT) were 
analyzed. The average baseline QRS width of the patients was 157 ± 22 ms. Sixteen 
patients had left bundle branch block, 7 had right bundle branch block, and 10 had non- 
specific intraventricular conduction delay. Analysis results demonstrated 29/29 VT and 9/ 
10 SV'F episodes were correctly diagnosed by VTC. 
Conclusion: In a prospective evaluation, VTC effectively classified spontaneous tachy- 
cardias from ICD patients with wide baseline QRS and rate sensing electrograms derived 
from widely split sensing electrodes. Clinical experience in ICDs equipped with V'I'C is 
expected to be at least similarly reliable. 
3:00 p.m. 
826-5 Randomized Prospective Study of  S ing le  Coi l  Versus 
Dual Coil Defibrillation in Patients With Ventrlcular 
Arry thmlas  Undergoing ICD Imp lantat ion  
Chdstoober A. Rinaldi. Ron D. Simon, Artur Baszko, Donna Elliott, Julian Bostock, 
Jaswinder S. Gill, Guys and St Thomas NHS Trust, London, United Kingdom. 
Background 
ICD implantation is standard therapy for malignant ventdcular arrythmias. The advantage 
of dual and single coil defibrillator leads in the successful conversion of arrythmias is 
unclear. In this study we compared the effectiveness of dual versus single coil defibrilla- 
tion leads. 
Methods and Results 
The study was a prospective, multi-centre, randomised study comparing a dual coil with 
a single coil defibrillation system as part of an Ice using an active pectoral electrode. 
Seventy six patients (64 men and 12 women; age 61 ± 11 years ) were implanted with 
either a dual (Group 1, n=38) or single coil lead system (Group 2, n=39). The patients 
represented a typical ICD cohort: 60 % presented with ischaemic cardiomyopathy as 
their primary cardiac disease, the mean left ventricular ejection fraction was 40.6 ± 15.8 
%. The primary tachyarrhythmia was monomorphic ventricular tachycardia (MVT) in 52.6 
% patients and ventdcular fibrillation in 38.4 %. There was no significant difference in 
terms of P and R wave amplitudes, pacing thresholds and lead impedance at implanta- 
tion and follow up in th(~ two groups. There was similarly no difference in terms of defibril- 
lation thresholds (DFT) at implantation. Patients in Group 1 had an average DFT of 
10.2±5.2J compared to a DFT of 10.3±4.1J in Group 2, p=NS. 
Conclusions 
Our study demonstrates no significant advantage of a dual coil lead system over a single 
coil system in terms of lead values and defibrillation thresholds. This may have important 
bearing on the choice of lead systems when implanting 
3:15 p.m. 
826-6 Implantab le  Def ibr i l la tor  Events  in Pat ients  With 
Hypertrophic Cardiomyopathy: Low Incidence of  
Ventrlcular and High Incidence of Supraventricular 
Events During Intermediate Term Follow-Up 
Andrea M. Russo, Christa Schorr, Jamie Springman, David Callans, Henry Hsia, Bindi 
Shah, Edca Zado, Francis E. Marchlinski, University of Pennsylvania Health System, 
Philadelphia, Pennsylvania. 
Background: Implantable cardioverter defibrillators (ICDs) are often implanted in high risk 
patients (pts) with hypertrophic cardiomyopathy (HCM), even without documented clini- 
cal sustained ventdcular arrhythmias. However, supraventdcular arrhythmias (SVAs) 
may also occur, leading to inappropriate therapy. 
Methods: We examined 21 pts with HCM who underwent ICD implantation at our center 
to determine the frequency of appropriate and inappropriate shocks during follow-up. 
Results: Mean age was 47 +/- 19, LVEF 65 +/- 12%, septal thickness 20 +/- 7 mm, and 
67% had a significant outflow gradient. Symptoms included syncope 9 pts, presyncope 9 
pts, cardiac arrest 2 pts, and none 1 pt. Eleven pts had inducible sustained ventricular 
tachycardia (VT) or ventricular fibrillation (VF). Dual chamber devices were implanted in 
10 pts. Nine pts underwent at least 1 generator replacement. All pts are alive (mean fol- 
low-up 23 +/- 24 months). 
Thirty detections occurred in the VF zone with 24 shocks and 16 aborted shocks. Shocks 
were delivered in 9 pts (43%). Appropriate therapy for monomorphic VT occurred in only 
1 pt (5%), 8 days following initial implant, and this pt initially presented with sustained VT. 
Inappropriate therapy was delivered for SVAs in 6 pts (29%) and artifact in 3 pts (14%). 
The SVA leading to shock therapy was felt to be sinus techycardia in 5 pts and atrial flut- 
ter in 1 pt. The mean number of months to the first sustained event was 30 +/- 33. Two 
pts experienced syncope or presyncope at follow-up, without associated arrhythmias. 
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Conclusions: In the described typical population of patients with HCM receiving ICDs: (1) 
There is a low incidence of appropriate shock therapy during an intermediate follow-up 
period, occurring in only 1 pt (5%). To date, no pts presenting with syncope or presyn- 
cope, without documented prior clinical arrhythmias, have experienced sustained v-r at 
follow-up, suggesting a possible non-arrhythmic mechanism for syncope. (2) In contrast, 
29% of pts expedanced inappropriate shocks, most often due to SVAs. Careful attention 
to device programming, or perhaps implantation of dual chamber devices with utilization 
of detection enhancements, may help reduce inappropriate therapy. 
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829 Atrial Fibrillation: Pharmacological 
Treatment 
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Georgia World Congress Center, Room 267W 
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829-1 The Relation of Magnesium Treatment and Blood 
Magnesium Levels With Development of Atr ia l  
F ibr i l la t ion After Coronary Artery Bypass Surgery 
Sinan Daodelen. Fevzi Toraman, Hasan Karabulut, Cem Alhan, Kosuyolu Heart and 
Research Hospital, Istanbul, Turkey, Acibadem Hospital, Istanbul, Turke~ 
It is well known that magnesium (Mg) treatment has beneficial effects on both ventricular 
and atrial arrhythmia. But there is no previous data concerning the relationship between 
blood Mg cutoff point level and atrial fibrillation (AF) developing after coronary bypass 
surgery, The aim of our study was to investigate the relationship between blood Mg lev- 
els and development of post bypass surgery AF and the effect of Mg treatment on AlE 
Method: A hundred and forty eight consecutive patients undergoing coronary artery 
bypass surgery (33F,115M; mean age 62.1±7.0 years) were enrolled to the study as two 
subgroups. Group A consisted of 93 pts to whom 1.5 g/day MgSO4 infusion were applied 
the day before surgery, just after operation, and 4 days following surgery, and Group B 
consisted of 55 control pts. Preoperative and postoperative 12 leads ECG recordings 
and blood Mg levels were analyzed daily for four days. Results: AF developed in 2 (2%) 
pts in group A and in 20 (36%) pts in group B (p<0.001). Baseline Mg level was similar in 
two groups. Fourth day Mg level was significantly higher in group A pts (2.21±0.23 vs 
1.9±0.14 mg/dl; p<0.001). When pts who developed AF and who did not were compared, 
baseline Mg level was similar. Fourth day Mg level was significantly lower in pts who 
developed AF after surgery (2.00±0.23 vs 2.15±0.26 mg/dl; p<0.001 ). When the relation- 
ship of Mg levels and AF development were investigated with ROC analysis, Mg cutoff 
point value was found to be 2.37 mg/dl, with very low sensitivity (18%) and specific- 
ity(12%). Conclusion: Mg treatment after coronary bypass surgery significantly reduces 
the risk of AlE The calculatsd cutoff point value of 2.37 mg/dl for Mg levels to impede AF 
is not predictive. 
2:15 p.m. 
829-2 A Prospective and Randomized Study on the Effect of 
an Ang lo tens in  II Type  I Receptor Blocker I rbesartan in 
Maintaining Sinus Rhythm in Patients With Persistent 
Atr ia l  F ibr i l la t ion 
Antonio Hernandaz-Meddd. Jose G. Rebollo, Anibal Rodriguez, Manuel G. Bueno, Lucas 
Cano, Jose Manuel Cano, Gonzalo Pef~a, Gonzalo Pens, Driss Melehi, Detalina Savova, 
Asuncion Camino, Concepcion Moro, Ramon y Cajal, Madrid, Spain, Alcala University, 
Madrid, Spain. 
Background: the tissue angiotensin II has been recently implicated in atrial electrical 
remodelling, but there is no clinical human study at this point. The main objective of our 
study was to evaluate the effects of an antagonist of angiotensin II receptors on the acute 
efficacy of external electrical cardioversion and the early recurrences of atrial fibrillation, 
during the acute phase of electrical remodelling, to test the hypothesis that the combina- 
tion of angiotensin II antagonists Irbesartan plus amiodarone is more efficaccious in pre- 
venting recurrent atrial fibrillation than amiodarone alone. 
Methods: This is an interventional, prospective, randomized and muiticenter study on 112 
patients with persistent atrial fibrillation. Patients must have had an episode of persistent 
atrial fibrillation (> 72 hours) and clinical indication of reversion to sinus rhythm. Two 
groups of patients were compared: Group I (56 patients) was treated with amiodarone 
and Group II (56 patients) was treated with amiodarone + Irbesartan. There were no clin- 
ical or echhocardiographic diferences between both groups. The primary and point was 
the length of time to a first recurrence of atrial fibrillation. 
Results: Pharmacologic conversion occurred in 13 (23%) patients of group I and 16 
(32%) of group II (p<0.O5). Cardioversion (electrical or pharmacological) was effective in 
87.5% of patients of group I and 96.5% of patients of group II (p<0.05). After 2 months of 
follow-up, 17 (30%) of the patients assigned to amiodarona and 6 (14%) of those 
assigned to amiodarone+irbasartan had a recurrence of atrial fibrillation (p<0.01), 
Conclusion: These results indicate for the first time in humans that the blockade of AT1 
receptor with irbesartan may lead to better therapeutic managment of patients with per- 
sistent atrial fibrillation. Pretreatment with an angiotansin II receptor antagonist during 
atdal fibrillation appeared to reduce recurrences, possibly due to a reduction of electrical 
remodeling. 
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829-3 Use of Dofetillde in the Treatment of Recurrent Atr ia l  
Fibrlllctlon: L imi ted  E f f i cacy  With Prior Drug Failures 
Andrea M. Russo, Christa Schorr, Brian Bixby, Henry Hsia, Mauraen Nicholas, David 
Callans, Francis E. Marehlinski, University of Pennsylvania Health System, Philadelphia, 
Pennsylvania. 
Background: Dofetilide (DOF) is a class III antiarrhythmic agent (AA) used to reduce 
recurrences of atrial fibrillation (AF). Because of more recent availability, and regulations 
regarding distribution, it is frequently used after other AA agents. 
Methods: We hypothesized that DOF has limited efficacy for AF following other AA fail- 
ures. Thirty-two patients (pts) with AF were treated with DOF after failing other AA 
agents. Dosing was based on creatinine clearance and adjustments based on QT inter- 
val. 
Results: Mean age was 62 +/- 13 years, LVEF 45 +/- 17%, and 20 were men. Structural 
heart disease was present in 21 pts. Pts underwent a mean of 2.6 (range 1 to 6) prior AA 
trials. All pts have been followed for at least 1 month after discharge. Thirteen pts (41%) 
remained on DOF at last follow-up (67 +/- 89 days). DOF was discontinued after 25 +/- 
37 days (range 2 to 164) in 19 pts. Reasons include inefficacy 14 pts (44%), intolerance 
3 pts (9%), and unacceptable increase in QT 2 pts (6%). No pts developed ventricular 
arrhythmias or syncope, and there were no deaths. A comparison was made of apparent 
drug responders versus those with AF recurrence. 
Conclusions: In response to DOF for AF in pts who failed prior AA therapy: 1) DOF is in 
general well-tolerated; 2) Recurrent AF is common (59%); 3) DOF appears more effec- 
tive in pts with structural heart disease, with AF diagnosed for a shorter pedod of time. 
This suggests a difference in arrhythmic substrate for AF in pts with and without overt 
heart disease, that may explain the response to DOlE 
Effective(13pts) Ineffective(14pts) p-value: 
Age 61 +/- 11 57+/- 15 NS 
% males 92% 50% 0.01 
# prior AA drugs 1.2 3.9 <0.01 
# pdor AA drugs failed 1.6 2.9 0.02 
# Class III failed 23% 57% NS 
LVEF (%) 40 +/- 15% 56 +/- 13% <0.01 
LA size (cm) 4.6 4.1 NS 
% no heart disease 15% 50% 0.02 
History CHF 46% 7% 0.03 
1st diagnosis AF (mths) 18 +/- 24 60 +/- 38 <0.01 
Mean dose (mcg/day) 846 911 NS 
2:45 p.m. 
829-4 Effects of Oral Flecainide and Amiodarone on Atr ia l  
Fibrillatory Frequency in Persistent Human Atrial 
F ibr i l la t ion 
Andreas Bollmann. Karl-Heinz Binias, Ines Toepffer, Reiko Steinert, Jochen Moiling, 
Sven Reek, Helmuf U. Klein, Christoph Geller, Department of Cardiology, University 
Hospital, Magdeburg, Gerrnan v 
Background: Class Ic and III antiarrhythmic drugs are effective in converting recent 
onset but not persistent atrial fibrillation (AF). The purpose of this study was (1) to inves- 
tigate the influence of both oral flecainide (flec) and amiodarona (amio) on atdal fibrilla- 
tory frequency (f) using spectral analysis of the surface ECG in persistent AF, and (2) to 
correlate f with drug-induced conversion. 
Methods: In 37 pts (23 male, mean age 61 years, LAD 45 ram) with AF lasting longer 24 
hours two minute ECG recordings from an orthogonal lead system were analyzed at 
baseline and after 3 days of antiarrhythmic drug treatment. Flec (n=17, 300 mg loading 
dose, 200 to 300 mg/d) and amio (n=20, 1200 mg/d loading dose) were given empirically 
depending on undedying heart disease prior to external electrical cardioversion. Determi- 
nation of f was performed using a three step algorithm (filtadng, QRST averaging and 
subtraction, discrete Fourier transformation of the fibrillatory baseline). 
Results: At baseline mean f measured 6.4 ± 0.5 Hz (range 5.5 to 7.7). Frequency was 
reduced by antiarrhythmic drugs in all pts by 1.4± 0.8 Hz (range 0.2 to 3.0, p<.001 vs 
baseline) with a greater f decrease following flec (2.2 ± 0.5 Hz) compared to amio (1.0 ± 
0.5 Hz, p<.001). Drug-related cardioversion was observed in 9/17 (53%) flec pts as 
opposed to 1/20 (5%) amio pt (p=.001). Sensitivity and specificity for predicting flec 
response were strongly related to f (AUC=.764 using ROC curve analysis). Maximal 
specificity (87 %) with adequate sensitivity (56 %) was present at a fibrillatory frequency 
> 6 Hz. There were no other predictors for drug-induced cardioversion. 
Conclusions: (1) The antifibdllatory effect of flec and amio may be directly monitored 
using spectral analysis of the surface ECG. (2) AF is likely be converted with an oral flec 
bolus when the atrial fibrillatory frequency is below 6 Hz. 
